
- Applied Clinical Trials-06-20-2006
- Volume 0
- Issue 0
Awards Ceremony
DIA President, Theresa Kane Musser, Executive Director, Development Operations, Rigel Pharmaceuticals, presented the awards
DIA President, Theresa Kane Musser, Executive Director, Development Operations, Rigel Pharmaceuticals, presented the awards, which were handed out in the following order:
Drug Information Journal Awards:
Drug Information Journal Student Award: Radhika Nair, MS, PhD, and Anju Parthan, MS, PhD
The Donald E. Francke Award for Overall Excellence in Journal Publishing: Scott Patterson, PhD, and Marilyn Agin, PhD
The Thomas W. Teal Award: William F. Rosenberger, PhD
The DIA Lifetime Membership:
- Dave Domann, MS, RPh, Senior Director, Healthcare Quality Management, Ortho-McNeil Janssen Scientific Affairs, Titusville, NJ.
The Outstanding Service Award:
- Herng-Der Chern, MD, PhD, Executive Director of Taiwan's Center for Drug Evaluation.
- Martin D. Hynes, III, PhD, Director of Product Research and Development, Eli Lilly and Company.
- Shigeru Kageyama, MD, PhD, Professor of Clinical Pharmacology and Therapeutics at Jikei University School of Medicine.
- Mohammed Razdar Khan, Director, Synergex Consulting, Ontario, Canada.
- Pulok K. Mukherjee, MPharm, PhD, FIC, Acting Director, the School of Natural Product Studies, Jadavpur University, Kolkata, India.
- Gary G. Walker, Associate Director, Global Data Integration Standards, Quintiles.
The First Founders Service Award:
- Michael R. Hamrell, PhD, RAC, editor-in-chief of the Drug Information Journal.
The Distinguished Career Award:
- Harry A. Guess, MD, PhD, who passed away in January 2006, was an active member of the association before serving as DIA President from 1992 to 1993.
Articles in this issue
about 20 years ago
Keynote Address: Making Medicine Meaningfulabout 20 years ago
Fighting Fraud and Noncomplianceabout 20 years ago
Every Potential Patient Is Preciousabout 20 years ago
U.S., EU Officials Provide Update on Parallel Scientific Advice Pilotabout 20 years ago
Considering the Critical Path in Oncology Drug Developmentabout 20 years ago
PROs and Drug Labeling Undergo Scrutinyabout 20 years ago
SAS Drug Development Adds Genomic-Analysis Capabilities



